Search Results

You are looking at 91 - 100 of 158 items for :

  • "systemic treatment" x
Clear All
Full access

Pooja Ghatalia and Elizabeth R. Plimack

-cell carcinoma . J Clin Oncol 1997 ; 15 : 2449 – 2455 . 10.1200/JCO.1997.15.6.2449 9196161 11. Roth AD , Fazio N , Stupp R , . Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic

Full access

Julie Hallet, Laura Davis, Alyson Mahar, Michail Mavros, Kaitlyn Beyfuss, Ying Liu, Calvin H.L. Law, Craig Earle and Natalie Coburn

patients have an indication for systemic therapy. However, across provider volume quintiles, only 44% to 47% of patients with PA received systemic treatment, with increased likelihood of treatment associated with HV providers. Nonreceipt of therapy may be

Full access

Johannes Uhlig, Michael Cecchini, Amar Sheth, Stacey Stein, Jill Lacy and Hyun S. Kim

and MSI might confound the prognostic profile of MSI. 47 Our study is not devoid of limitations, which are mainly inherent to the use of NCDB as the data source. First, given the stratified coding of the NCDB, no distinction between specific systemic

Full access

Tara M. Mackay, Anouk E.J. Latenstein, Mirjam A.G. Sprangers, Lydia G. van der Geest, Geert-Jan Creemers, Susan van Dieren, Jan-Willem B. de Groot, Bas Groot Koerkamp, Ignace H. de Hingh, Marjolein Y.V. Homs, Evelien J.M. de Jong, I. Quintus Molenaar, Gijs A. Patijn, Lonneke V. van de Poll-Franse, Hjalmar C. van Santvoort, Judith de Vos-Geelen, Johanna W. Wilmink, Casper H. van Eijck, Marc G. Besselink, Hanneke W.M. van Laarhoven and for the Dutch Pancreatic Cancer Group

Mandatory Measurements in Pancreatic Cancer Trials (COMM-PACT) for systemic treatment of unresectable disease . Lancet Oncol 2018 ; 19 : e151 – e160 . 10.1016/S1470-2045(18)30098-6 16. Veenhoven R . How do we assess how happy we are? Tenets

Full access

William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns and Rashmi Kumar

for Breast Cancer are available at NCCN.org . The primary goals of systemic treatment of recurrent/stage IV breast cancer are palliating symptoms, prolonging survival, and maintaining or improving quality of life. Hormone receptor (HR) status, human

Full access

Kelly G. Paulson and Shailender Bhatia

62% (CR, 14%; PR, 48%). 45 Pembrolizumab Pembrolizumab is a humanized IgG4 anti–PD-1 monoclonal antibody that is being investigated in a phase II trial for first-line systemic treatment of immunocompetent patients with unresectable stage IIIB

Full access

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

Featured Updates to the NCCN Guidelines

Shaji K. Kumar, Natalie S. Callander, Jens Hillengass, Michaela Liedtke, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, Jason C. Chandler, Robert F. Cornell, Caitlin Costello, Yvonne Efebera, Matthew Faiman, Alfred Garfall, Kelly Godby, Leona Holmberg, Myo Htut, Carol Ann Huff, Yubin Kang, Ola Landgren, Ehsan Malek, Thomas Martin, James Omel, Noopur Raje, Douglas Sborov, Seema Singhal, Keith Stockerl-Goldstein, Carlyn Tan, Donna Weber, Alyse Johnson-Chilla, Jennifer Keller and Rashmi Kumar

significance. 14 – 17 Zamagni et al 17 reported progression-free survival (PFS) of 44 months in patients with residual focal lesions on FDG-PET/CT versus 84 months for those with no residual focal lesions after systemic treatment ( P =.0009). In the IMAJEM

Full access

Philip J. Saylor and Matthew R. Smith

effective systemic treatment for prostate cancer. Whether accomplished through bilateral orchiectomies or treatment with a gonadotropin-releasing hormone (GnRH) agonist, ADT leads to severe hypogonadism. GnRH agonists, for instance, lower serum testosterone

Full access

Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Ryan C. Fields, Martin D. Fleming, Brian Gastman, Rene Gonzalez, Valerie Guild, Douglas Johnson, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I. Ross, April K. Salama, Joseph Skitzki, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian and Anita Engh

metastatic disease. See the full NCCN Guidelines for Melanoma for the complete recommendations for treatment of metastatic melanoma, including non-systemic treatment modalities and treatment of brain metastases. Systemic Therapy for Advanced Melanoma

Full access

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Thomas Dilling, Michael Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, Scott J. Swanson, James Stevenson, Kurt Tauer, Stephen C. Yang, Kristina Gregory and Miranda Hughes

. Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review . Expert Rev Respir Med 2015 ; 9 : 533 – 549 . 59. Christoph DC Eberhardt WE . Systemic treatment of malignant pleural mesothelioma